prestim and Body-Weight

prestim has been researched along with Body-Weight* in 1 studies

Trials

1 trial(s) available for prestim and Body-Weight

Article	Year
Long-term follow-up of 500 patients with mild to moderate hypertension who had successfully completed a 3-month general practice study of a timolol-bendrofluazide combination ('Prestim'). Current medical research and opinion, 1987, Volume: 10, Issue:8 A sample of 500 patients with mild to moderate hypertension, who had been successfully controlled on once daily timolol/bendrofluazide at the end of a 3-month general practice study, was followed up after approximately 1 year of treatment. Physicians who had participated in the trial were questioned on the current status of these patients. Out of 479 reports received, data showed that 358 (75%) patients were still normotensive 47 weeks after starting treatment with timolol/bendrofluazide and in a further 8 patients other antihypertensive agents had been added to this therapy. Of the 113 patients no longer receiving timolol/bendrofluazide, only 38 (7.9%) had stopped therapy due to adverse effects. It is concluded that the results are a further indication that timolol/bendrofluazide offers an acceptable and balanced long-term form of therapy in hypertension for both the patient and the physician. Topics: Adult; Aged; Bendroflumethiazide; Body Weight; Clinical Trials as Topic; Drug Combinations; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Pulse; Timolol	1987

Article

Year

Long-term follow-up of 500 patients with mild to moderate hypertension who had successfully completed a 3-month general practice study of a timolol-bendrofluazide combination ('Prestim').

Current medical research and opinion, 1987, Volume: 10, Issue:8

A sample of 500 patients with mild to moderate hypertension, who had been successfully controlled on once daily timolol/bendrofluazide at the end of a 3-month general practice study, was followed up after approximately 1 year of treatment. Physicians who had participated in the trial were questioned on the current status of these patients. Out of 479 reports received, data showed that 358 (75%) patients were still normotensive 47 weeks after starting treatment with timolol/bendrofluazide and in a further 8 patients other antihypertensive agents had been added to this therapy. Of the 113 patients no longer receiving timolol/bendrofluazide, only 38 (7.9%) had stopped therapy due to adverse effects. It is concluded that the results are a further indication that timolol/bendrofluazide offers an acceptable and balanced long-term form of therapy in hypertension for both the patient and the physician.

Topics: Adult; Aged; Bendroflumethiazide; Body Weight; Clinical Trials as Topic; Drug Combinations; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Pulse; Timolol

1987